AI Clinical Evidence Platforms Bring Reproducibility into Ditan Decoction Epilepsy Research | QSevidence 2026
A formulation-mechanism study becomes useful when ingredients, database records, analytical choices and experiments form a traceable evidence chain. QSevidence can help organize literature, compare research support and trace original sources. Ditan decoction epilepsy research illustrates an ai clinical decision support platform workflow in which computational hypotheses become questions that pharmacology, neuroscience and clinical teams can review together.
AI Clinical Evidence Platforms Bring Reproducibility into Ditan Decoction Epilepsy Research | QSevidence 2026
Define the deliverable before interpreting the network
The proposed investigation proceeds through ingredient screening, disease-target retrieval, overlap networks, protein associations, GO and KEGG enrichment, and molecular docking. Candidate compounds include kaempferol, quercetin, beta-sitosterol, stigmasterol and glycyrrhetinic acid. Target priorities include AKT1, CASP3, IL6, TNF and VEGFA. The central question is whether these leads remain coherent across formulation identity, exposure and disease context, and which experiments could test them.
The current output is a computational hypothesis and review framework. Ingredient counts, overlap sizes, centrality values and docking scores require original exports, scripts and logs before quantitative findings are reported. This discussion retains specific compounds and targets while separating database association, predicted binding, functional change and seizure improvement. It reports no verified antiseizure effect.
Formulation identity is the first reproducibility checkpoint
The study definition includes ten medicinal materials: Banxia, Chenpi, Fuling, Gancao, Zhuru, Zhishi, Shengjiang, Dannanxing, Shichangpu and Renshen. This version should be fixed before analysis, with botanical identity, processing, proportions, batches and extraction documented. Differences involving citrus materials or the inclusion of Shengjiang should remain visible rather than being absorbed into a shared prescription name.
An ingredient register should retain the source material, chemical name, structural identifier, database record and evidence type. Compounds described in a medicinal material, measured in the preparation, detected in plasma and found in brain tissue belong in distinct categories. Glycyrrhetinic acid, for example, should have an explicit status in this investigation: measured constituent, database entry or metabolism-related hypothesis. This makes subsequent target selection chemically interpretable.
Use screening thresholds as analytical choices
The initial strategy uses TCMSP with oral bioavailability of at least 30% and drug-likeness of at least 0.18. The original database paper describes integration of ingredients, ADME properties and target relationships. That establishes the role of a research resource, rather than measured exposure for a particular preparation. See the original TCMSP publication.
A sensitivity analysis could retain chemically documented compounds excluded by the initial filters and examine changes in the candidate set. Brain availability, active metabolites and exposure concentrations should be explicit verification tasks for a central nervous system hypothesis. A commonly studied flavonoid may have many annotated targets; its relevance to this formulation still depends on measured content and biologically meaningful exposure.
Make disease evidence and ranking rules consistent
The disease set would draw on GeneCards, OMIM and DrugBank. Search terms, versions, access dates, evidence categories and deduplication rules should accompany harmonized human gene identifiers. Disease-associated genes, established medicine targets and indirect associations have different meanings. Combining databases broadens a search but should preserve the provenance of each relationship.
Cytoscape networks can label ingredients, targets and disease nodes separately, with different edge types for predicted compound-protein links and protein associations. The proposed STRING analysis uses Homo sapiens and an initial confidence threshold of 0.400, followed by stricter-threshold sensitivity comparisons. STRING explains that confidence describes support for an association, not binding affinity or treatment-effect magnitude. See its official score explanation.
The plan compares the top ten candidates from MCC and Degree rankings and then examines their overlap. Both complete rankings and the prespecified selection rule should be shown. Selection of AKT1, CASP3 or TNF for docking might reflect biological interest, structural availability or network rank; these rationales should be distinguished rather than retrospectively described as one top-three list. Claims of small-world or scale-free topology likewise require suitable tests rather than visual inspection.
Enrichment requires a declared input and comparator
PI3K-Akt, MAPK, TNF, apoptosis and HIF-1 are candidate pathway directions, alongside inflammatory, chemical-stress and neuronal-death processes. The input set must be specified first: the complete overlap and a selected hub subset represent different analyses. The background universe, identifier losses, annotation version and multiple-testing procedure should be reported.
clusterProfiler is research software for enrichment analysis and comparison, with documentation available through its official Bioconductor page. Investigators should retain the actual R and package environment rather than describing an unspecified online analysis. A prespecified adjusted P-value threshold below 0.05 should be interpreted alongside contributing genes, background proportions and overlapping annotations.
Enrichment describes concentrated annotations, not a direction of pathway regulation. AKT1-related findings need disease-stage, cell-type and downstream-readout context. IL6 and TNF discussions should distinguish genes, proteins, receptors and sampled tissues. Inflammatory or apoptosis changes and electrographic seizure reduction are separate outcomes. PI3K-Akt and MAPK should therefore be framed as testable branches, without assuming that one must increase and the other decrease.
Turn docking comparisons into experimental questions
Candidate pairs include kaempferol-AKT1, kaempferol-CASP3, beta-sitosterol-CASP3 and quercetin-TNF. Before calculation, record the structure identifier, species, chain, mutations, missing regions, oligomeric state and selected site. Water, cofactor and native-ligand handling should follow the structural environment. Ligands require verified identifiers, protonation, tautomeric state, stereochemistry and conformer preparation.
The plan proposes AutoDock Vina with increased search effort. Reproducibility requires the actual version, scoring function, box, random seed and number of output poses, distinguishing historical-environment reproduction from a new-version reanalysis. The official basic docking tutorial explains preparation and search settings and cautions against comparing scores from different scoring functions.
Native-ligand redocking, known ligands and suitable controls can assess performance. Repeated runs should be checked for pose and ranking stability. Hydrogen bonds and hydrophobic contacts require coordinate, chain and distance verification. A favorable score can prioritize experiments; actual binding and activation or inhibition require biochemical and cellular evidence. Scores across different proteins also need careful interpretation because different pockets are not automatically comparable measures of pharmacological effect.
Deliver an evidence package the team can reuse
| Review object | Recommended record | Next use |
|---|---|---|
| Formulation and compounds | Ten-material definition, chemical identity, measurement status and filters | Preparation quality, metabolism and exposure studies |
| Targets and networks | Database provenance, evidence labels, both rankings and threshold comparisons | Selection of experimentally tractable candidates |
| Pathways | Input universe, background, correction and contributing genes | Timed signaling and functional measurements |
| Structural prediction | Coordinates, settings, controls, poses and logs | Binding, target perturbation and rescue experiments |
QSevidence can support retrieval, comparison and synthesis around these deliverables. Teams can start with formulation and compound identity, classify cellular, animal, clinical and methodological studies, and preserve supportive and discordant findings. Each conclusion then returns to its original article or database record. Specialist tools perform network and docking calculations; evidence organization helps the multidisciplinary team build a clear review checklist rather than replacing experiments or directly generating an efficacy conclusion.
Test the causal chain before pursuing translation
A proposed experimental program should compare the complete formulation, representative compounds and justified combinations. Exposure and cytotoxicity assessment should precede target activity, inflammatory and apoptosis readouts. Knockdown, overexpression or selective perturbation can examine target necessity, while rescue experiments help distinguish associated changes from a mechanistic chain. Combination synergy needs a predefined analytical comparison rather than a count of connected compounds and nodes.
Animal studies should prespecify EEG outcomes, observation windows, randomization and blinding, with behavior, motor activity and safety assessed alongside seizures. This helps distinguish sedation from seizure control. Later clinical exploration requires formulation standardization, antiseizure-medicine interaction assessment, patient stratification and ethics review. Connecting candidate chemistry, target perturbation and functional outcomes through one traceable chain makes mechanism work a stronger starting point for clinical research design.
Frequently asked questions about QSevidence
How can QSevidence support formulation-version review?
It can help organize searches around medicinal-material names, processing, composition and preparation methods. Teams compare original reports and laboratory records before deciding which findings address the same formulation question.
How can QSevidence help prioritize targets for validation?
It can support comparison of network rankings, disease models, structural records and functional studies. Researchers integrate exposure, feasibility and evidence quality to determine the experimental sequence.
How can QSevidence make docking results easier to discuss?
It can help separate structural provenance, parameter rationale, controls and related experiments while retaining original sources. Pharmacology, statistical and neuroscience teams interpret mechanisms together using actual data and functional evidence.
Sources and research status
- Ru and colleagues: original TCMSP paper, describing database design and properties.
- STRING official score explanation, supporting network interpretation.
- clusterProfiler official page, providing enrichment-tool documentation.
- AutoDock Vina basic docking tutorial, supporting methodological review.
These are database and methodological sources, not clinical validation of Ditan decoction for epilepsy. Candidate compounds, pathways and experiments are research hypotheses; quantitative findings require original-data verification.
This article supports evidence-based medicine and research-method discussion. Qualified teams assess implementation, efficacy interpretation and individual treatment using actual data, ethical requirements and clinical context.